id: NEW:interferon_based_hcv_treatment_to_NEW:treatment_adverse_events_hemodialysis_patients
name: Interferon-Based HCV Treatment â†’ Treatment Adverse Events in Hemodialysis Patients
from_node:
  node_id: NEW:interferon_based_hcv_treatment
  node_name: Interferon-Based HCV Treatment
to_node:
  node_id: NEW:treatment_adverse_events_hemodialysis_patients
  node_name: Treatment Adverse Events in Hemodialysis Patients
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Interferon-based HCV treatment (conventional or pegylated interferon) is
  administered to hemodialysis patients with hepatitis C infection'
- 'Step 2: Interferon induces systemic inflammatory and immunomodulatory responses,
  causing flu-like syndrome in approximately 41% of patients'
- 'Step 3: Bone marrow suppression from interferon leads to cytopenia, with high rates
  of anemia particularly problematic in dialysis patients who already have impaired
  erythropoietin production'
- 'Step 4: Additional adverse events manifest across multiple organ systems including
  thyroid dysfunction, gastrointestinal problems, central nervous system effects,
  cardiovascular complications, and increased infection risk'
- 'Step 5: Severe adverse events lead to treatment discontinuation in approximately
  11% of patients, with immunological complications including prior graft rejection
  in transplant candidates'
evidence:
  quality_rating: A
  n_studies: 38
  primary_citation: 'T Casanovas Taltavull et al. 2009. Results of hepatitis C virus
    treatment in patients on hemodialysis: data from published meta-analyses in 2008.
    Transplantation proceedings.'
  supporting_citations: []
description: Interferon-based HCV treatment in hemodialysis patients causes multiple
  adverse events including flu-like syndrome (41%), anemia, cytopenia, thyroid dysfunction,
  gastrointestinal problems, CNS effects, cardiovascular complications, infectious
  problems, and immunological reactions including graft rejection. Approximately 11%
  of patients require treatment discontinuation due to severe adverse events. The
  hemodialysis population is particularly vulnerable due to pre-existing anemia and
  altered drug pharmacokinetics.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 41.0
    type: percentage
    ci_lower: null
    ci_upper: null
  p_value: null
  sample_size: 1104
moderators:
- name: Interferon type (pegylated vs conventional)
  direction: weakens
  strength: weak
  description: Pegylated interferon provided few additional benefits over conventional
    interferon in terms of efficacy, but adverse event profiles were similar
- name: HCV genotype
  direction: strengthens
  strength: moderate
  description: Genotype 1 patients had lower SVR rates (33%) requiring potentially
    longer treatment exposure and cumulative adverse events
- name: Erythropoietin use
  direction: weakens
  strength: moderate
  description: Use of erythropoietin, IV iron, or transfusions can mitigate anemia
    though not consistently reported
